• Publications
  • Influence
The Parkinson Progression Marker Initiative (PPMI)
The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding ofExpand
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo. Expand
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Fourteen years after transplantation into the striatum of an individual with Parkinson's disease, grafted nigral neurons were found to have Lewy body–like inclusions that stained positively forExpand
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Early treatment with rasagiline at a dose of 1 mg per day provided benefits that were consistent with a possible disease-modifying effect, but early treatment with the two doses were associated with different outcomes, the study results must be interpreted with caution. Expand
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Ropinirole is associated with slower progression of PD than levodopa as assessed by 18F‐dopa PET, and this prospective, 2‐year, randomized, double‐blind, multinational study compared the rates of loss of dopamine‐terminal function in de novo patients with clinical and 18F-dopaPET evidence of early PD. Expand
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease.
Grafts of fetal mesencephalic tissue can survive for a long period in the human brain and restore dopaminergic innervation to the striatum in patients with Parkinson's disease. Expand
Long-term evaluation of deep brain stimulation of the thalamus.
Thalamic stimulation is safe and effective for the long-term management of essential and Parkinsonian tremors and Bilateral stimulation can cause dysarthria and incoordination and should be used cautiously. Expand
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and
Findings show that rasagiline delayed the need for symptomatic antiparkinsonian drugs and emphasise the contribution of the UPDRS ADL in the response of the rasgeiline 1 mg per day early-start versus delayed-start groups. Expand
High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor
Chronic high‐frequency stimulation of the ventral intermedius nucleus of the thalamus is safe and highly effective in ameliorating essential and parkinsonian tremor and measures of function were significantly improved in patients with essential tremor. Expand
Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
Patients with higher baseline UPDRSm scores and studies that focused on PD with motor fluctuations, surgical interventions, or those with a higher probability of placebo assignment showed increased odds of positive placebo response. Expand